Wellington Management Group
LAB icon

Wellington Management Group’s Standard BioTools LAB Stock Holding History

Wellington Management Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-630,277
Closed -$3.59M – 2257
2017
Q1 		$3.59M Buy
630,277
+14,814
+2% +$93.9K ﹤0.01% 1562
2016
Q4 		$4.48M Buy
615,463
+14,110
+2% +$88.6K ﹤0.01% 1437
2016
Q3 		$4.82M Sell
601,353
-51,163
-8% -$470K ﹤0.01% 1393
2016
Q2 		$5.89M Sell
652,516
-308,554
-32% -$2.9M ﹤0.01% 1290
2016
Q1 		$7.76M Buy
961,070
+213,670
+29% +$1.54M ﹤0.01% 1232
2015
Q4 		$8.08M Buy
747,400
+113,932
+18% +$1.12M ﹤0.01% 1233
2015
Q3 		$5.14M Buy
+633,468
New +$9.97M ﹤0.01% 1348
2015
Q1 		– Sell
-130,180
Closed -$4.39M – 2206
2014
Q4 		$4.39M Buy
+130,180
New +$3.69M ﹤0.01% 1473
2014
Q1 		– Sell
-104,800
Closed -$4.02M – 2194
2013
Q4 		$4.02M Buy
+104,800
New +$3.09M ﹤0.01% 1526

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group's LAB Position: Q2 2017 in Review

Wellington Management Group sold out of Standard BioTools (LAB) in Q2 2017, closing a stake of 630,277 shares — an estimated $3.59M sold.

Wellington Management Group first reported a position in LAB in Q4 2013 and held it in 9 quarters. The position peaked at $8.08M in Q4 2015. 80 funds tracked by Wall St. Rank hold LAB as of Q2 2017.

  • Wellington Management Group reported no remaining Standard BioTools position as of Q2 2017 after selling out during the quarter.
  • Wellington Management Group sold 630,277 Standard BioTools shares in Q2 2017, an estimated $3.59M.
  • Wellington Management Group first reported a position in Standard BioTools in Q4 2013 and held it in 9 quarters.
  • Wellington Management Group's Standard BioTools position peaked at $8.08M in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2017.

Based on Wellington Management Group's 13F filing for Q2 2017, filed 14 Aug 2017.